SODIUM PHENYLACETATE AND SODIUM BENZOATE Drug Patent Profile
✉ Email this page to a colleague
When do Sodium Phenylacetate And Sodium Benzoate patents expire, and when can generic versions of Sodium Phenylacetate And Sodium Benzoate launch?
Sodium Phenylacetate And Sodium Benzoate is a drug marketed by Ailex Pharms Llc, Maia Pharms Inc, and Navinta Llc. and is included in five NDAs.
The generic ingredient in SODIUM PHENYLACETATE AND SODIUM BENZOATE is sodium benzoate; sodium phenylacetate. There are one thousand four hundred and seventy-two drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the sodium benzoate; sodium phenylacetate profile page.
Summary for SODIUM PHENYLACETATE AND SODIUM BENZOATE
| US Patents: | 0 |
| Applicants: | 3 |
| NDAs: | 5 |
| Finished Product Suppliers / Packagers: | 7 |
| Raw Ingredient (Bulk) Api Vendors: | 2 |
| Clinical Trials: | 4 |
| Patent Applications: | 1 |
| Formulation / Manufacturing: | see details |
| What excipients (inactive ingredients) are in SODIUM PHENYLACETATE AND SODIUM BENZOATE? | SODIUM PHENYLACETATE AND SODIUM BENZOATE excipients list |
| DailyMed Link: | SODIUM PHENYLACETATE AND SODIUM BENZOATE at DailyMed |
Recent Clinical Trials for SODIUM PHENYLACETATE AND SODIUM BENZOATE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Takeda | Phase 1 |
| Horizon Pharma Ireland, Ltd., Dublin Ireland | Phase 2 |
| Horizon Pharma Ireland, Ltd., Dublin Ireland | Phase 1 |
See all SODIUM PHENYLACETATE AND SODIUM BENZOATE clinical trials
Pharmacology for SODIUM PHENYLACETATE AND SODIUM BENZOATE
| Drug Class | Nitrogen Binding Agent |
| Mechanism of Action | Ammonium Ion Binding Activity |
Anatomical Therapeutic Chemical (ATC) Classes for SODIUM PHENYLACETATE AND SODIUM BENZOATE
US Patents and Regulatory Information for SODIUM PHENYLACETATE AND SODIUM BENZOATE
SODIUM PHENYLACETATE AND SODIUM BENZOATE is protected by zero US patents and one FDA Regulatory Exclusivity.
FDA Regulatory Exclusivity protecting SODIUM PHENYLACETATE AND SODIUM BENZOATE
COMPETITIVE GENERIC THERAPY
Exclusivity Expiration: ⤷ Try a Trial
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ailex Pharms Llc | SODIUM PHENYLACETATE AND SODIUM BENZOATE | sodium benzoate; sodium phenylacetate | SOLUTION;INTRAVENOUS | 207096-001 | Feb 24, 2016 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Navinta Llc | SODIUM PHENYLACETATE AND SODIUM BENZOATE | sodium benzoate; sodium phenylacetate | SOLUTION;INTRAVENOUS | 205880-001 | Aug 4, 2016 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Maia Pharms Inc | SODIUM PHENYLACETATE AND SODIUM BENZOATE | sodium benzoate; sodium phenylacetate | SOLUTION;INTRAVENOUS | 208521-001 | May 8, 2017 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Maia Pharms Inc | SODIUM PHENYLACETATE AND SODIUM BENZOATE | sodium benzoate; sodium phenylacetate | SOLUTION;INTRAVENOUS | 215025-001 | Jun 10, 2021 | AP | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Navinta Llc | SODIUM PHENYLACETATE AND SODIUM BENZOATE | sodium benzoate; sodium phenylacetate | SOLUTION;INTRAVENOUS | 217526-001 | Jul 14, 2023 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
